Literature DB >> 30392769

Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study.

Joakim Esbjörnsson1, Fredrik Månsson2, Anders Kvist3, Zacarias J da Silva4, Sören Andersson5, Eva Maria Fenyö6, Per-Erik Isberg7, Antonio J Biague4, Jacob Lindman3, Angelica A Palm2, Sarah L Rowland-Jones8, Marianne Jansson6, Patrik Medstrand2, Hans Norrgren3.   

Abstract

BACKGROUND: HIV type 2 (HIV-2) is considered more benign and has fewer pathogenic consequences than HIV type 1 (HIV-1) for most infected individuals. However, reliable estimates of time to AIDS and mortality among those with HIV-2 infection are absent. We therefore aimed to compare the time to AIDS and mortality, and the CD4 T-cell dynamics between those infected with HIV-1 and HIV-2.
METHODS: We did a prospective open cohort study. We included all police officers with regular employment from police stations in both urban and rural areas of Guinea-Bissau since Feb 6, 1990. We continued to include participants until Sept 28, 2009, and follow-up of HIV-1-positive and HIV-2-positive individuals continued until Sept 28, 2013. We collected blood samples at enrolment and at scheduled annual follow-up visits at police stations. We analysed longitudinal data from individuals infected with HIV-1 and HIV-2 according to time to AIDS, time to death, and T-cell dynamics. Time of HIV infection was estimated as the mid-timepoint between last HIV-seronegative and first HIV-seropositive sample. Data from an additional 2984 HIV-uninfected individuals from the same population were analysed to assess the effect of natural mortality on HIV-related mortality.
FINDINGS: 872 participants tested HIV positive during the 23-year study period: 408 were infected with HIV-1 (183 infected before and 225 infected after enrolment) and 464 were infected with HIV-2 (377 before and 87 after enrolment). The median time from HIV infection to development of AIDS was 6·2 years (95% CI 5·4-7·1) for HIV-1 infection and 14·3 years (10·7-18·0) for HIV-2 infection (p<0·0001). The median survival time after HIV infection was 8·2 years (95% CI 7·5-8·9) for HIV-1 infection and 15·6 years (12·0-19·2) for HIV-2 infection (p<0·0001). Individuals who were infected with HIV-1 or HIV-2 before enrolment showed similar results. Comparison with uninfected individuals indicated limited confounding contribution from natural mortality. Mean CD4 percentages were higher in individuals with HIV-2 than in those with HIV-1 during early infection (28·0% [SE 1·3] vs 22·3% [1·7]; p=0·00094) and declined at a slower rate (0·4% [0·2] vs 0·9% [0·2] per year; p=0·028). HIV-2-infected individuals developed clinical AIDS at higher mean CD4 percentages (18·2%, IQR 7·2-25·4) than HIV-1-infected individuals (8·2%, 3·0-13·8; p<0·0001).
INTERPRETATION: Our results show that both HIV-1-infected and HIV-2-infected individuals have a high probability of developing and dying from AIDS without antiretroviral treatment. FUNDING: Swedish International Development Agency, Swedish Research Council, Swedish Society of Medical Research, Medical Faculty at Lund University, and Region Skåne Research and Development.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2018        PMID: 30392769     DOI: 10.1016/S2352-3018(18)30254-6

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  18 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

3.  HIV-2 Drug Resistance Genotyping from Dried Blood Spots.

Authors:  Dana N Raugi; Robert S Nixon; Sally Leong; Khadim Faye; Jean Phillipe Diatta; Fatima Sall; Robert A Smith; ElHadji Ibrahima Sall; Jean Jacques Malomar; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 5.948

4.  Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Authors:  Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

Review 5.  Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.

Authors:  M T Boswell; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

6.  Quantification of HIV-2 DNA in Whole Blood.

Authors:  Zsófia Szojka; Sara Karlson; Marianne Jansson; Patrik Medstrand
Journal:  Bio Protoc       Date:  2019-10-20

7.  Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Authors:  Dana N Raugi; Selly Ba; Ousseynou Cisse; Khardiata Diallo; Ibrahima Tito Tamba; Cheikh Ndour; Ndeye Mery Dia Badiane; Louise Fortes; Mouhamadou Baïla Diallo; Dominique Faye; Robert A Smith; Fatima Sall; Macoumba Toure; ElHadji Ibrahima Sall; Habibatou Diallo Agne; Khadim Faye; Jean Philippe Diatta; Marie Pierre Sy; Ming Chang; Binetou Diaw; Jacques Sambou; Raphael Bakhoum; Mame Demba Sy; Alassane Niang; Jean Jacques Malomar; Robert W Coombs; Stephen E Hawes; Ibra Ndoye; Nancy B Kiviat; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2021-02-01       Impact factor: 20.999

8.  Distribution of HbS Allele and Haplotypes in a Multi-Ethnic Population of Guinea Bissau, West Africa: Implications for Public Health Screening.

Authors:  Maddalena Martella; Mimma Campeggio; Gift Pulè; Ambroise Wonkam; Federica Menzato; Vania Munaretto; Giampietro Viola; Sabado P Da Costa; Giulia Reggiani; Antonia Araujo; Dionisio Cumbà; Giuseppe Liotta; Laura Sainati; Fabio Riccardi; Raffaella Colombatti
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.569

9.  Novel assays to investigate the mechanisms of latent infection with HIV-2.

Authors:  Michael D Lu; Sushama Telwatte; Nitasha Kumar; Fernanda Ferreira; Holly Anne Martin; Gayatri Nikhila Kadiyala; Adam Wedrychowski; Sara Moron-Lopez; Tsui-Hua Chen; Erin A Goecker; Robert W Coombs; Chuanyi M Lu; Joseph K Wong; Athe Tsibris; Steven A Yukl
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

10.  Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection.

Authors:  Marco Iannetta; Stéphane Isnard; Jennifer Manuzak; Jean-Baptiste Guillerme; Mathilde Notin; Karine Bailly; Muriel Andrieu; Sonia Amraoui; Lene Vimeux; Suzanne Figueiredo; Bénédicte Charmeteau-de Muylder; Laura Vaton; Etienne X Hatton; Assia Samri; Brigitte Autran; Rodolphe Thiébaut; Nathalie Chaghil; David Glohi; Charlotte Charpentier; Diane Descamps; Françoise Brun-Vézinet; Sophie Matheron; Remi Cheynier; Anne Hosmalin
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.